Buy, Sell, Or Hold ABBV Stock At $185?
1. AbbVie beat Q4 estimates with $15.1B revenue and $2.16 EPS. 2. Skyrizi and Rinvoq sales grew significantly, aiding revenue despite Humira's decline. 3. Market uncertainty may impact ABBV, but company outlook suggests strong growth ahead. 4. ABBV stock rose 5% after earnings, but has underperformed S&P 500 recently. 5. 2025 earnings estimates are slightly better than analysts' forecasts, indicating stability.